Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax® at Blau Farmacêutica S.A. Compared to Eprex®, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.

NCT01695759 is registered in ClinicalTrials.gov with Azidus Brasil as lead sponsor.

NCT NCT01695759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01695759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax® at Blau Farmacêutica S.A. Compared to Eprex®, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.
Lead sponsor
Azidus Brasil
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2013
Completion date
January 31, 2018
Enrollment
92 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, chronic kidney disease